Literature DB >> 8564234

Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation.

W S Lee1, V Limmroth, C Ayata, F M Cutrer, C Waeber, X Yu, M A Moskowitz.   

Abstract

1. The GABA transaminase inhibitor and activator of glutamic acid decarboxylase, valproic acid is being used for the treatment of migraine. Its mechanism of action is unknown. We tested the effects of sodium valproate and GABAA-agonist muscimol on dural plasma protein ([125I]-bovine serum albumin) extravasation evoked by either unilateral trigeminal ganglion stimulation (0.6 mA, 5 ms, 5 Hz, 5 min) or substance P (SP) administration (1 nmol kg-1,i.v.) in anaesthetized Sprague-Dawley rats. 2. Intraperitoneal (i.p.) injection of sodium valproate or muscimol, but not baclofen (< or = 10 mg kg-1, i.p.) dose-dependently reduced dural plasma protein extravasation caused either by electrical trigeminal stimulation (ED50: 6.6 +/- 1.4 mg kg-1, i.p., and 58 +/- 18 micrograms kg-1, i.p. for valproate or muscimol, respectively) or by intravenous substance P administration (ED50: 3.2 +/- 1.4 mg kg-1, i.p. and 385 +/- 190 micrograms kg-1, i.p. for valproate or muscimol, respectively). 3. Valproate (6.6 mg kg-1, i.p.) or muscimol (58 micrograms kg-1, i.p.) had no effect on mean arterial blood pressure or heart rate when measured for 30 min after i.p. administration. 4. The GABAA-antagonist bicuculline (0.01 mg kg-1, i.p.) completely reversed the effect of valproate and muscimol on plasma extravasation following electrical stimulation or substance P administration, whereas the GABAB-receptor antagonist, phaclofen (0.01-1 mg kg-1, i.p.) did not. Bicuculline or phaclofen, given alone, did not alter the plasma extravasation response after either electrical stimulation or SP administration. 5. Valproate decreased plasma extravasation following substance P administration in adult animals, neonatally treated with capsaicin by a bicuculline-reversible mechanism. This suggests that GABAA receptors are not found primarily on those afferent neurones or fibres which are sensitive to capsaicin treatment in neonatal rats.6. We conclude that sodium valproate blocks plasma extravasation in the meninges through GABAA mediated postjunctional receptors probably within the meninges. The dosages required are comparable to those used clinically. Agonists and modulators at the GABAA receptor may become useful for the development of selective therapeutic agents for migraine and cluster headache.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564234      PMCID: PMC1908914          DOI: 10.1111/j.1476-5381.1995.tb16388.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo.

Authors:  R Hering; A Kuritzky
Journal:  Cephalalgia       Date:  1992-04       Impact factor: 6.292

Review 2.  GABAB receptor pharmacology.

Authors:  N G Bowery
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

3.  Effects of injury discharge on the persistent expression of spinal cord fos-like immunoreactivity produced by sciatic nerve transection in the rat.

Authors:  S I Chi; J D Levine; A I Basbaum
Journal:  Brain Res       Date:  1993-07-23       Impact factor: 3.252

4.  Coexpression of GABAA receptor gamma 1 and gamma 2 subunits in the rat trigeminal ganglion.

Authors:  E Kondo; H Kiyama; T Araki; T Shida; Y Ueda; M Tohyama
Journal:  Brain Res Mol Brain Res       Date:  1994-02

5.  Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development.

Authors:  G W Rebeck; K I Maynard; B T Hyman; M A Moskowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation.

Authors:  V Dimitriadou; M G Buzzi; T C Theoharides; M A Moskowitz
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

Review 7.  Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.

Authors:  M A Moskowitz
Journal:  Trends Pharmacol Sci       Date:  1992-08       Impact factor: 14.819

8.  CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges.

Authors:  K Nozaki; M A Moskowitz; P Boccalini
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

9.  Joint inflammation and hyperalgesia are reduced by spinal bicuculline.

Authors:  K A Sluka; W D Willis; K N Westlund
Journal:  Neuroreport       Date:  1993-11-18       Impact factor: 1.837

10.  Disposition of sumatriptan in laboratory animals and humans.

Authors:  C M Dixon; D A Saynor; P D Andrew; J Oxford; A Bradbury; M H Tarbit
Journal:  Drug Metab Dispos       Date:  1993 Sep-Oct       Impact factor: 3.922

View more
  21 in total

1.  Neuropeptide Y Y2 receptor-mediated attenuation of neurogenic plasma extravasation acting through pertussis toxin-sensitive mechanisms.

Authors:  X J Yu; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

2.  Homocysteine causes cerebrovascular leakage in mice.

Authors:  David Lominadze; Andrew M Roberts; Neetu Tyagi; Karni S Moshal; Suresh C Tyagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-10-28       Impact factor: 4.733

3.  Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin.

Authors:  F M Cutrer; V Limmroth; G Ayata; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

4.  Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes.

Authors:  A A Parsons; S Bingham; P Raval; S Read; M Thompson; N Upton
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  5-HT7 Receptors Are Not Involved in Neuropeptide Release in Primary Cultured Rat Trigeminal Ganglion Neurons.

Authors:  Xiaojuan Wang; Rong Hu; Jianbo Liang; Ze Li; Weiwen Sun; Xiaoping Pan
Journal:  J Mol Neurosci       Date:  2016-02-18       Impact factor: 3.444

6.  GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges.

Authors:  V Limmroth; W S Lee; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

7.  Homocysteine alters cerebral microvascular integrity and causes remodeling by antagonizing GABA-A receptor.

Authors:  David Lominadze; Neetu Tyagi; Utpal Sen; Alexander Ovechkin; Suresh C Tyagi
Journal:  Mol Cell Biochem       Date:  2012-08-12       Impact factor: 3.396

Review 8.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 9.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

10.  Targeting the central projection of the dural trigeminovascular system for migraine prophylaxis.

Authors:  Simon Akerman; Marcela Romero-Reyes
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-08       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.